chartexchange

Cellectar Biosciences Inc (CLRB) (Q3 2026) Earnings Call Highlights: Strong Post-BTK Data and ...

GuruFocus | Nov 12, 2026 6:03 PM EST

Cellectar Biosciences Inc (CLRB) reported a 79.2% major response rate in post-BTK Waldenström macroglobulinemia patients and remains on track to dose its first Phase 3 patient in Q1 2027 and submit… Related Stocks: CLRB ,

Read original article